These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 23764182)
1. Duration of trastuzumab for HER2-positive breast cancer. Montemurro F; Aglietta M Lancet Oncol; 2013 Jul; 14(8):678-9. PubMed ID: 23764182 [No Abstract] [Full Text] [Related]
2. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A; Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181 [TBL] [Abstract][Full Text] [Related]
3. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments. Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890 [TBL] [Abstract][Full Text] [Related]
6. How we treat locally advanced HER2-positive breast cancer. Exman P; Pernas S; Tolaney SM Clin Adv Hematol Oncol; 2019 May; 17(5):271-280. PubMed ID: 31188804 [No Abstract] [Full Text] [Related]
7. POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer. Goel S; Winer EP Oncology (Williston Park); 2015 Nov; 29(11):797-8, 802. PubMed ID: 26573058 [No Abstract] [Full Text] [Related]
8. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670 [TBL] [Abstract][Full Text] [Related]
9. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice. Bonifazi M; Franchi M; Rossi M; Zambelli A; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E Breast; 2014 Oct; 23(5):573-8. PubMed ID: 24934637 [TBL] [Abstract][Full Text] [Related]
10. Targeting alternative pathways in HER2-positive breast cancer. Rastogi P Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739 [No Abstract] [Full Text] [Related]
11. NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer. Elsada A; Doss S; Robertson J; Adam EJ Lancet Oncol; 2016 Feb; 17(2):143-144. PubMed ID: 26703893 [No Abstract] [Full Text] [Related]
13. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002 [TBL] [Abstract][Full Text] [Related]
14. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer. Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S J BUON; 2013; 18(1):44-50. PubMed ID: 23613387 [TBL] [Abstract][Full Text] [Related]
15. Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors. Frati A; Chereau E; Coutant C; Bezu C; Antoine M; Chopier J; Daraï E; Uzan S; Gligorov J; Rouzier R Breast Cancer Res Treat; 2012 Apr; 132(2):601-7. PubMed ID: 22160638 [TBL] [Abstract][Full Text] [Related]
17. [A Case of HER2-Positive Breast Cancer with Liver Metastases Showing Three Years of Complete Response to Combination Therapy with Trastuzumabplus Pertuzumab]. Fujimoto Y; Yamaguchi K; Ueno A; Sakurai R; Nagahisa Y; Imai S; Kawamoto K Gan To Kagaku Ryoho; 2018 Mar; 45(3):459-461. PubMed ID: 29650905 [TBL] [Abstract][Full Text] [Related]
18. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available. Bianchi GV; Duca M; Sica L; Mariani G Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801 [TBL] [Abstract][Full Text] [Related]
19. HER2 testing in patients with breast cancer. Dixon JM; Wilson V; Verrill M; Symmans WF BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887 [No Abstract] [Full Text] [Related]
20. Ten years of HER2-directed therapy: still questions after all these years. Krop IE; Winer EP Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974 [No Abstract] [Full Text] [Related] [Next] [New Search]